Cumulatively, swertiamarin targets potential metabolic regulators AMPK and PPAR-α, through which it regulates hepatic glycemic load, fat accumulation, insulin resistance, and ROS in hepatic steatosis, which emphasizes the clinical importance of swertiamarin in regulating metabolism and as a suitable candidate for the treatment of hepatic steatosis [51]. This evidence concerns the gene PPARA and fatty liver disease.